Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Potenza Therapeutics

- PMLiVE

Regulatory struggles force Aveo to cut 140 jobs

Expects FDA rejection for tivozanib in kidney cancer

- PMLiVE

Talking about a successful merger

How communications can support effective mergers and acquisitions outcomes

- PMLiVE

Orphan status in US for Astellas/ Basilea antifungal

Isavuconazole is being developed as a treatment for invasive aspergillosis

- PMLiVE

Amgen boosts Japan prospects with Astellas partnership

Companies establish joint venture and plan to co-develop new medicines

- PMLiVE

AstraZeneca offers $443m to buy Omthera

Adds to list of deals to boost flagging pipeline

- PMLiVE

A look back at Sanofi’s merger with Synthélabo

This month, in 1999: How two pharma companies came together to create a giant

- PMLiVE

Astellas gets first OK for prostate drug Vesomni

Approved in the Netherlands to treat men with lower urinary tract symptoms

- PMLiVE

Royalty Pharma raises Elan bid as deals keep coming

Values Elan at about $6.5bn

- PMLiVE

Actavis to buy Warner Chilcott in $8.5bn deal

Combined company will have annual revenues of about $11bn

Bayer symbol

Bayer boosts consumer care business with Steigerwald purchase

Fuels ambition to become world leader in OTC medicines

National Institute for Health and Care Excellence NICE logo

NICE recommends Astellas’ Betmiga for overactive bladder

Final draft guidance recommends Vesicare successor

- PMLiVE

FDA expands use of Roche/ Astellas’ Tarceva in lung cancer patients

New indication approved alongside companion diagnostic to detect gene mutation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links